Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Ovid Therapeutics Inc.

Ticker
OVID
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include initiation of analyst coverage with positive ratings, quarterly financial results showing losses but some revenue progress, and ongoing clinical advancement of key pipeline programs.

Recent developments:
  • Cantor Fitzgerald initiated coverage of Ovid Therapeutics with an overweight rating in October 2026 [N3].
  • Ovid reported a Q2 2026 net loss but revenue exceeded expectations, indicating operational progress [N4].
  • The company’s Q4 2025 earnings and revenues surpassed estimates, reflecting positive financial developments [N7].
  • Ovid is advancing clinical programs with planned Phase 2 studies for OV329 in tuberous sclerosis complex and infantile spasms, and Phase 1 trials for OV4071 in 2026 [S1].
Overview

Ovid Therapeutics Inc. is dedicated to developing small molecule medicines targeting neuronal hyperexcitability in brain disorders such as epilepsies and psychoses. The company focuses on novel mechanisms of action to address significant unmet medical needs by modulating neurotransmitters and ion channels to restore neuronal balance. Its pipeline includes five clinical-stage programs, with assets like OV329, a GABA-aminotransferase inhibitor, and OV4071, a KCC2 direct activator, aimed at treating drug-resistant seizures and neuropsychiatric symptoms. Ovid pursues a strategy combining in-licensing, collaborations, and academic partnerships to advance its pipeline. Financially, the company reported a net loss and maintains liquidity with a strong current ratio as of Q3 2026. It faces risks related to capital requirements, clinical development, regulatory approvals, and market acceptance.

Executive summary

Ovid Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for brain disorders characterized by neuronal hyperexcitability, including epilepsy and psychosis. The company has a diversified pipeline with five clinical-stage programs targeting drug-resistant seizures and neuropsychiatric conditions, including OV329 and OV4071. Financially, as of September 30, 2026, Ovid reported $13.8 million in cash and equivalents, a strong current ratio of 11.97, and a net loss of $20.78 million for the quarter. The company has no approved products or revenues from drug sales and faces risks typical of early-stage biopharmaceutical firms, including capital needs and clinical development uncertainties. Recent analyst coverage and clinical progress provide insight into its operational status. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for OVID

Bull case model:

Ovid Therapeutics has developed a diversified pipeline of small molecule drug candidates addressing significant unmet needs in epilepsy and neuropsychiatric disorders. Its lead programs, including OV329 and OV4071, have demonstrated favorable safety and tolerability in early clinical studies, supporting further development. The company's approach of targeting fundamental neuronal mechanisms with novel MoAs could differentiate its therapies in the market. Strategic collaborations and multiple clinical-stage programs provide optionality and potential value-creating milestones. Recent analyst coverage and clinical progress indicate external recognition of its scientific and commercial potential.

Bear case model:

Ovid Therapeutics faces typical risks of early-stage biopharmaceutical companies, including the need for substantial additional capital to fund operations and clinical development. Its drug candidates remain in clinical or preclinical stages with no approved products or revenues, and clinical trial outcomes are uncertain. Regulatory approval and market acceptance challenges could delay or prevent commercialization. The company’s financial losses and accumulated deficit highlight ongoing operating risks. Macroeconomic factors and market volatility may further impact its ability to raise capital and execute its business strategy.

Moat:

Ovid Therapeutics' moat lies in its focus on differentiated small molecule therapies targeting fundamental biological mechanisms of neuronal hyperexcitability, an area with significant unmet medical need and limited recent innovation. Its pipeline includes potential first-in-class or best-in-class candidates with novel mechanisms such as GABA-aminotransferase inhibition and KCC2 activation. The company's strategy of combining in-licensing with academic collaborations enhances its scientific expertise and pipeline robustness. However, as a clinical-stage biopharmaceutical company without approved products, its moat depends on successful clinical development and regulatory approvals, which remain uncertain.

Risks overview
Risks summary
The most significant risks for Ovid Therapeutics include the need for additional capital to fund ongoing operations and clinical development, and the inherent uncertainties in clinical trial outcomes and regulatory approvals.
Risks details:

• Capital Requirements and Financing Risk: Ovid requires additional capital to finance operations and clinical development. Failure to secure funding on acceptable terms could delay, limit, or terminate drug development efforts or operations [S2].
• Clinical Development and Regulatory Risk: The company’s drug candidates are in clinical or preclinical stages. Clinical trials are expensive, time-consuming, and uncertain. Failure to demonstrate safety and efficacy or obtain regulatory approvals would adversely affect the business [S2].
• Market Acceptance Risk: Even if approved, drug candidates may fail to achieve market acceptance by physicians, patients, or payors, limiting commercial success [S2].
• Operational and Macroeconomic Risks: Economic downturns, inflation, interest rate changes, trade policies, geopolitical events, and supply chain disruptions may negatively impact operations and financial performance [S2].
• Intellectual Property and Competition Risk: Inability to obtain or maintain patent protection or competition from other therapies could impair competitive position [S2].

FINAL FORECAST FOR OVID

Final take one line
Ovid Therapeutics is a clinical-stage biopharmaceutical company with a differentiated CNS-focused pipeline and strong SEC disclosure, facing typical early-stage development and capital risks.
Final take 12 to 24 month view

Business trends: Continued clinical advancement of small molecule CNS therapies targeting neuronal hyperexcitability with multiple programs progressing through early and late-stage trials.
Execution milestones: Initiation and completion of Phase 1 and Phase 2 clinical trials for lead candidates OV329 and OV4071, regulatory interactions, and potential business development partnerships.
Key risks: Need for additional capital, clinical and regulatory uncertainties, market acceptance challenges, and macroeconomic factors impacting operations and financing.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines targeting brain disorders characterized by neuronal hyperexcitability, including epilepsies, psychoses, and other CNS conditions [S1].
  • The company aims to develop differentiated medicines that modulate fundamental biological targets such as neurotransmitters and ion channels to restore neuronal balance and reduce symptoms like seizures and psychosis [S1].
  • Ovid's pipeline includes five clinical-stage drug development programs, with two in late-stage trials, targeting drug-resistant focal onset seizures, developmental and epileptic encephalopathies (including tuberous sclerosis complex and infantile spasms), psychosis associated with Parkinson's disease and Lewy body dementia, and schizophrenia [S1].
  • Key pipeline assets include OV329, a next-generation GABA-aminotransferase inhibitor with favorable safety and tolerability profiles demonstrated in Phase 1 studies, and OV4071, an oral KCC2 direct activator entering Phase 1 clinical trials [S1].
  • The company pursues a strategy of in-licensing and collaborations to build its pipeline, complemented by academic partnerships to support translational research [S1].
  • Ovid's R&D approach emphasizes small molecule compounds with precise mechanisms of action, validated targets, and prioritization of safety and tolerability to enable chronic use and polypharmacy compatibility [S1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $13.8 million, current assets of $141.96 million, current liabilities of $11.86 million, a current ratio of 11.97, and a cash ratio of 1.16, indicating strong liquidity [S2].
  • The company reported a net loss of $20.78 million for the quarter ended September 30, 2026, and an accumulated deficit of $374.5 million as of that date [S2].
  • Ovid has no approved commercial products and has not generated revenue from drug sales; its revenues, if any, will depend on successful clinical development and regulatory approvals [S1,S2].
  • The company faces significant risks including the need for additional capital, potential delays or failures in clinical development, regulatory approval uncertainties, and market acceptance challenges [S2].
  • Recent news includes Cantor Fitzgerald initiating coverage with an overweight rating and multiple analyst buy/outperform recommendations, reflecting external interest in the company [N3].
  • Ovid reported Q2 2026 loss but revenue exceeded expectations, and Q4 2025 earnings and revenues surpassed estimates, indicating some operational progress [N4,N7].
  • The company is advancing clinical programs with planned Phase 2 studies for OV329 in tuberous sclerosis complex and infantile spasms, and Phase 1 trials for OV4071 in 2026 [S1].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-18 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-06 | www.nasdaq.com | Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/anika-therapeutics-anik-beats-q3-earnings-and-revenue-estimates
  • N2 | 2026-11-05 | www.nasdaq.com | Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/vera-therapeutics-inc-vera-reports-q3-loss-tops-revenue-estimates
  • N3 | 2026-10-09 | www.nasdaq.com | Cantor Fitzgerald Initiates Coverage of Ovid Therapeutics with Overweight Rating | https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-ovid-therapeutics-overweight-rating
  • N4 | 2026-08-13 | www.nasdaq.com | Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/ovid-therapeutics-ovid-reports-q2-loss-beats-revenue-estimates
  • N5 | 2026-08-06 | www.nasdaq.com | Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/lexicon-pharmaceuticals-lxrx-reports-q2-loss-lags-revenue-estimates
  • N6 | 2026-08-05 | www.nasdaq.com | Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline | https://www.nasdaq.com/articles/earnings-preview-ovid-therapeutics-ovid-q2-earnings-expected-decline
  • N7 | 2026-03-18 | www.nasdaq.com | Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/ovid-therapeutics-ovid-q4-earnings-and-revenues-surpass-estimates
  • N8 | 2026-03-04 | www.nasdaq.com | Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/niagen-bioscience-nage-tops-q4-earnings-and-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine